TIME-DEPENDENT VARIABILITY OF D-DIMER LEVEL IN BLOOD SAMPLE OF COVID POSITIVE PATIENT
DOI:
https://doi.org/10.71000/4a5jcw37Keywords:
COVID-19, D-Dimer, , Fibrinolysis, Prognosis, SARS-CoV-2, Thrombosis, , Time FactorsAbstract
Background: Coronavirus disease 2019 (COVID-19) has emerged as a global health crisis, causing significant morbidity and mortality. Beyond its respiratory manifestations, it has profound systemic effects, particularly on the cardiovascular system, where it predisposes patients to hypercoagulability and disseminated intravascular coagulation (DIC). D-dimer, a fibrin degradation product, is widely used as a biomarker to assess thrombotic activity and disease progression. Establishing whether storage time influences D-dimer values is essential for ensuring laboratory accuracy and reliability, especially under strained healthcare conditions.
Objective: This study aimed to evaluate the effect of short-term storage time on D-dimer levels in samples from COVID-19–positive patients compared with healthy controls.
Methods: A case–control study was conducted at Hayatabad Medical Complex, Peshawar, between June and August 2021. A total of 100 participants were enrolled, including 50 confirmed COVID-19–positive patients and 50 healthy controls. Venous blood samples (2 mL) were collected in sodium citrate tubes from the antecubital vein of each participant and analyzed using a Cobas c501 analyzer. Samples were tested immediately (0 hours), after 4 hours, and after 8 hours at room temperature. Patients with comorbidities were excluded. Paired sample t-tests were applied to assess time-related differences in D-dimer values, and Pearson correlation was used to explore associations between time and D-dimer levels.
Results: In COVID-19–positive patients, the mean baseline D-dimer level was 3.77 ± 3.71 µg/mL FEU, increasing slightly to 3.81 ± 3.73 at 4 hours and 4.00 ± 3.80 at 8 hours. The corresponding two-tailed p-values were 0.366 and 0.174, both above the 0.05 threshold, indicating no statistically significant variation over time. Controls maintained consistently low D-dimer levels (0.69 ± 0.40 at baseline, 0.68 ± 0.39 at 4 hours, and 0.70 ± 0.39 at 8 hours) with p-values of 0.159. Pearson correlation revealed a weak, clinically negligible association between time and D-dimer levels.
Conclusion: D-dimer values in COVID-19–positive samples remained stable over 8 hours of storage at room temperature, confirming that short-term delays in analysis do not compromise test accuracy. This stability enhances the practical utility of D-dimer testing in clinical laboratories, particularly during peak workloads in pandemics.
References
Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020 May 1;109.
Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol [Internet]. 2021 Jan 4 [cited 2023 Sep 20];105(2):441–55.
Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest [Internet]. 2020 May 1 [cited 2023 Sep 20];130(5):2202–5.
Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 — Studies Needed. N Engl J Med [Internet]. 2020 Mar 26 [cited 2023 Sep 20];382(13):1194–6.
Abid K, Bari YA, Younas M, Tahir Javaid S, Imran A. Progress of COVID-19 Epidemic in Pakistan. Asia-Pacific J public Heal [Internet]. 2020 May 1 [cited 2023 Sep 20];32(4):154–6.
Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist [Internet]. 2020 Jun 1 [cited 2023 Sep 20]; 21:22–7.
Kong W, Agarwal PP. Chest imaging appearance of covid-19 infection. Radiol Cardiothorac Imaging [Internet]. 2020 Feb 1 [cited 2023 Sep 20];2(1).
Wu Z, Zhang R, Liu D, Liu X, Zhang J, Zhang Z, et al. Acute Respiratory Distress Syndrome Caused by Human Adenovirus in Adults: A Prospective Observational Study in Guangdong, China. Front Med. 2022 Jan 27;8.
Ladikou EE, Sivaloganathan H, Milne KM, Arter WE, Ramasamy R, Saad R, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond). 2020;20(5):e178-e82.
Bruno AM, Allshouse AA, Benson AE, Yost CC, Metz TD, Varner MW, et al. Thrombotic Markers in Pregnant Patients with and without SARS-CoV-2 Infection. Am J Perinatol. 2024;41(S 01):e3202-e9.
Kahlon N, Kaur J, Doddi S, Burmeister C, Sheikh T, Abuhelwa Z, et al. Risk Factors Associated With Six-Month Mortality in Hospitalized COVID-19 Patients: A Single-Institution Study. Cureus. 2022;14(11):e31206.
Kruger RA, du Plessis J, Muller H. Pulmonary embolism diagnosis with D-dimer levels and computed tomography. Health SA. 2024;29:2620.
Ahmed HS, Ahmed HS. The potential role of dyslipidemia in COVID-19 severity among Iraqi patients. Hum Antibodies. 2024;32(4):229-37.
Eslamifar Z, Behzadifard M, Zare E. Investigation of homocysteine, D-dimer and platelet count levels as potential predictors of thrombosis risk in COVID-19 patients. Mol Cell Biochem. 2025;480(1):439-44.
Al-Hashimi NH, Al-Hindawi MS, Mohsen AM, Al-Gebori AM. Enoxaparin Effect on Interleukin-10 Levels in Iraqi Patients with COVID-19: A Case-Control Study. Front Biosci (Schol Ed). 2024;16(2):9.
Ahmad I. Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized COVID-19 patients. J Pak Med Assoc. 2024;74(7):1345-50.
Cugno M, Meroni PL, Consonni D, Griffini S, Grovetti E, Novembrino C, et al. Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients. Microorganisms. 2022;10(6).
Srivastava A, Rengaraju M, Srivastava S, Narayan V, Gupta V, Upadhayay R. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):130.
Velasco-Rodríguez D, Alonso-Dominguez JM, Vidal Laso R, Lainez-González D, García-Raso A, Martín-Herrero S, et al. Development and validation of a predictive model of in-hospital mortality in COVID-19 patients. PLoS One. 2021;16(3):e0247676.
Kumano O, Ieko M, Komiyama Y, Naito S, Yoshida M, Takahashi N, et al. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis. Int J Lab Hematol. 2021;43(4):813-20.
de Carvalho SC, Raboni SM, Bueno LB, Lapinscki BA, Lissa SM, Amadeu LLM, et al. Assessment of the relationship between hematologic parameters, (CPD), in screening for COVID-19 severity in women. Future Sci OA. 2025;11(1):2540749.
Hassan Shah SST, Naeem I, Wahid B. Analyzing Correlation of Clinical Severity of COVID-19 with Other Biochemical Parameters: A Retrospective Study from Pakistan. Tohoku J Exp Med. 2021;255(4):315-23.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Said Wali, Emad Ud Din , Umar Gul , Rizwan Ullah, Abdur Rehman (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
